Evidence map›Paper›PMID 39965299›Full record

ArticleVaccine2025

Costing approaches for vaccine-preventable disease surveillance: Lessons from Ethiopia and Nepal.

Roopa Darwar, Xiaoxian Huang, Aschalew Abayeneh, Senait Alemayehu Beshah, Minal K Patel, Eden Dagnachew Zeleke, Mesfin Wossen, Mikias Alayu, Leuel Lisanwork, Benjamin A Dahl and 7 more

Abstract read
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Roopa DarwarGlobal Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: rdarwar@umich.edu.
Xiaoxian HuangWorld Health Organization, Geneva, Switzerland. Electronic address: xhuang@who.int.
Aschalew AbayenehDepartment of Public Health Emergency Management, Ethiopian Public Health Institute, Addis Ababa, Ethiopia. Electronic address: ascheabay@gmail.com.
Senait Alemayehu BeshahDepartment of Public Health Emergency Management, Ethiopian Public Health Institute, Addis Ababa, Ethiopia. Electronic address: senaitalb@gmail.com.
Minal K PatelGlobal Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, GA, United States; World Health Organization, Geneva, Switzerland. Electronic address: mkpatel@cdc.gov.
Eden Dagnachew ZelekeGlobal One Health Initiative, The Ohio State University, Addis Ababa, Ethiopia. Electronic address: edendagnuz@gmail.com.
Mesfin WossenDepartment of Public Health Emergency Management, Ethiopian Public Health Institute, Addis Ababa, Ethiopia. Electronic address: mesfinwossen@gmail.com.
Mikias AlayuDepartment of Public Health Emergency Management, Ethiopian Public Health Institute, Addis Ababa, Ethiopia. Electronic address: mikiasalayu7@gmail.com.
Leuel LisanworkGlobal One Health Initiative, The Ohio State University, Addis Ababa, Ethiopia. Electronic address: aragael@who.int.
Benjamin A DahlGlobal Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: bdahl@cdc.gov.
Eshetu Wassie AsemahaegneEthiopia Country Office, World Health Organization, Addis Ababa, Ethiopia. Electronic address: wassieasemahaegn@who.int.
Shu-Hua WangThe Ohio State University, Global One Health initiative and College of Medicine, Internal Medicine Department, Infectious Disease Division, Columbus, OH, United States. Electronic address: shu-hua.wang@osumc.edu.
Sarah Wood PallasGlobal Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: spallas@cdc.gov.
Ebba AbateGlobal One Health Initiative, The Ohio State University, Addis Ababa, Ethiopia. Electronic address: ewaktola@projecthope.org.
Jason M MwendaWorld Health Organization, Regional Office for Africa, Brazzaville, Democratic Republic of the Congo. Electronic address: mwendaj@who.int.
Anindya Sekhar BoseWorld Health Organization, Geneva, Switzerland; Nepal Country Office, World Health Organization, Kathmandu, Nepal. Electronic address: bosea@who.int.
Nelly MejiaGlobal Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: nelly.mejiagonzalez@cdc.hhs.gov.

Funding

Intramural CDC HHS CC999999World Health Organization 001
6 · The paper itself

Abstract

introductionThere is limited information about vaccine-preventable disease (VPD) surveillance cost. To address this gap, retrospective micro-costing studies of pre-COVID-19 pandemic VPD surveillance were conducted in Nepal and Ethiopia. Based on these evaluations-the sole cost evaluations on comprehensive VPD surveillance-this article provides methodological considerations and recommendations for other countries planning to conduct VPD surveillance costing studies to inform planning and budgeting.

methodsThe methods used for each study were systematically compared by key themes: costing perspective, cost categories, costing approach, allocation of shared costs, sampling criteria, extrapolation strategies, data collection, and analytic adjustments. For each theme, investigators identified methodologic challenges and potential strategies to address them, compared study methodologies to surveillance costing guidelines, and recommended practices for future such studies.

resultsThe studies used similar perspectives and VPD inclusion criteria. Costs in Nepal were collected and analyzed by a subset of surveillance core and support functions, whereas the Ethiopia study categorized costs using surveillance support functions from the Global Strategy on Comprehensive VPD Surveillance. A mix of random and purposive sampling of surveillance sites was used in both studies. Surveillance sites were selected considering the strata of interest at each administrative level. Results from both studies were extrapolated country-wide using sampling weights and assumptions about the representativeness of purposively sampled units. DISCUSSION: The review highlighted potential methodologic tradeoffs in utility and precision of results based on the lessons learned from two country VPD surveillance cost studies. The advantages of collecting and using cost estimates by VPD surveillance core versus support function for program budgeting for varied audiences should be explored in future studies. Sampling strategies should be developed with consideration for the precision needed for the intended use of costing results. The resulting recommendations can improve and standardize the conduct and interpretation of future such studies.

Indexed as

COVID-19Vaccine-Preventable DiseasesCosts and Cost AnalysisEthiopiaHumansNepalRetrospective StudiesVaccinationCostEconomic evaluationEthiopiaNepalPolio transitionVaccine-preventable disease surveillance

Identifiers

PMID39965299
PMCPMC13138381

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.